Filippo Lodi

List of Publications by Year
in descending order

48 papers	1,642 citations	361413 20 h-index	289244 40 g-index
49 all docs	49 docs citations	49 times ranked	2370 citing authors

#	Article	IF	Citations
1	Influence of Trigger PSA and PSA Kinetics on ¹¹C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy. Journal of Nuclear Medicine, 2009, 50, 1394-1400.	5.0	230
2	18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1601-1610.	6.4	204
3	Early Biochemical Relapse After Radical Prostatectomy: Which Prostate Cancer Patients May Benefit from a Restaging¹¹C-Choline PET/CT Scan Before Salvage Radiation Therapy?. Journal of Nuclear Medicine, 2014, 55, 1424-1429.	5.0	118
4	PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 365-84.	1.0	109
5	68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5Âng/ml. Efficacy and impact on treatment strategy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 11-19.	6.4	96
6	11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1971-1979.	6.4	79
7	68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 31-39.	6.4	74
8	Incidence of Increased ⁶⁸Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT. Journal of Nuclear Medicine, 2011, 52, 886-890.	5.0	57
9	11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 878-886.	6.4	54
10	Automation synthesis modules review. Applied Radiation and Isotopes, 2013, 76, 38-45.	1.5	50
11	Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2122-2130.	6.4	42
12	Assessment of radionuclidic impurities in 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG) routine production. Applied Radiation and Isotopes, 2008, 66, 295-302.	1.5	40
13	Synthesis and quality control of 68Ga citrate for routine clinical PET. Nuclear Medicine Communications, 2009, 30, 542-545.	1.1	38
14	Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Annals of Oncology, 2009, 20, 213-226.	1.2	37
15	Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With 64Cu-ATSM PET/CT. Clinical Nuclear Medicine, 2016, 41, e87-e92.	1.3	32
16	Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT?. Journal of Nuclear Cardiology, 2017, 24, 746-749.	2.1	31
17	Production of Ga-68 with a General Electric PETtrace cyclotron by liquid target. Physica Medica, 2018, 55, 116-126.	0.7	29
18	11C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma. Tumori, 2009, 95, 382-384.	1.1	28

#	Article	IF	Citations
19	A simple Tracerlab module modification for automated on-column [11C]methylation and [11C]carboxylation. Applied Radiation and Isotopes, 2007, 65, 691-695.	1.5	25
20	Synthesis of oncological [11C]radiopharmaceuticals for clinical PET. Nuclear Medicine and Biology, 2012, 39, 447-460.	0.6	24
21	C-11 Acetate Does Not Enhance Usefulness of F-18 FDG PET/CT in Differentiating Between Focal Nodular Hyperplasia and Hepatic Adenoma. Clinical Nuclear Medicine, 2009, 34, 659-665.	1.3	21
22	11C-meta-hydroxyephedrine PET/CT imaging allows in vivo study of adaptive thermogenesis and white-to-brown fat conversion. Molecular Metabolism, 2013, 2, 153-160.	6.5	21
23	Evaluation of an Automated Module Synthesis and a Sterile Cold Kitâ€“Based Preparation of ⁶⁸Ga-PSMA-11 in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 716-722.	5.0	20
24	Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. Molecular Imaging and Biology, 2010, 12, 616-625.	2.6	17
25	Radiolabelling, quality control and radiochemical purity assessment of the Octreotide analogue 68Ga DOTA NOC. Applied Radiation and Isotopes, 2008, 66, 1091-1096.	1.5	16
26	Overview and Perspectives on Automation Strategies in 68Ga Radiopharmaceutical Preparations. Recent Results in Cancer Research, 2013, 194, 17-31.	1.8	16
27	Generator Breakthrough and Radionuclidic Purification in Automated Synthesis of 68Ga-DOTANOC. Current Radiopharmaceuticals, 2013, 6, 72-77.	0.8	15
28	Reliability and reproducibility of N-[11C]methyl-choline and L-(S-methyl-[11C])methionine solid-phase synthesis: a useful and suitable method in clinical practice. Nuclear Medicine Communications, 2008, 29, 736-740.	1.1	14
29	11C-Meta-Hydroxyephedrine. Clinical Nuclear Medicine, 2015, 40, e96-e103.	1.3	14
30	Development of a modular system for the synthesis of PET [11C]labelled radiopharmaceuticals. Applied Radiation and Isotopes, 2009, 67, 1869-1873.	1.5	12
31	Molecular Imaging of Neuroblastoma Progression in TH-MYCN Transgenic Mice. Molecular Imaging and Biology, 2013, 15, 194-202.	2.6	12
32	Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. Clinical and Experimental Medicine, 2009, 9, 199-205.	3.6	10
33	Monte Carlo modeling provides accurate calibration factors for radionuclide activity meters. Applied Radiation and Isotopes, 2014, 94, 158-165.	1.5	8
34	Early and delayed evaluation of solid tumours with 64Cu-ATSM PET/CT. Nuclear Medicine Communications, 2017, 38, 340-346.	1.1	8
35	Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1661-1671.	6.4	8
36	[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 390-409.	6.4	7

#	Article	IF	Citations
37	Use of 65Zn as a tracer for the assessment of purification in the 68Ga-DOTANOC synthesis. Applied Radiation and Isotopes, 2013, 80, 27-31.	1.5	4
38	Single Subcutaneous Prostate Cancer Metastasis Detected by 68Ga-PSMA PET/CT During Early Biochemical Relapse: A Case Report. Clinical Genitourinary Cancer, 2019, 17, e356-e359.	1.9	4
39	The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis. Cancers, 2021, 13, 1575.	3.7	4
40	An innovative gamma-ray spectrometry system using a compact and portable CZT detector for radionuclidic purity tests of PET radiopharmaceuticals. Radiation Effects and Defects in Solids, 2016, 171, 726-735.	1.2	3
41	Quality Control of PET Radiopharmaceuticals. , 2017, , 105-126.		3
42	Acceptance Tests and Quality Control of Ge/ Ga Generators. Current Radiopharmaceuticals, 2009, 2, 165-168.	0.8	3
43	Synthesis of [11C]-meta-Hydroxyephedrine ([11C]MHED). , 0, , 191-198.		2
44	Automated synthesis of [11C]meta hydroxyephedrine, a PET radiopharmaceutical for studying sympathetic innervation in the heart. , 2008, , .		1
45	Synthesis of [11C]Acetate. , 0, , 297-303.		1
46	Chemistry of PET Radiopharmaceuticals: Labelling Strategies. , 2017, , 79-103.		1
47	18F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse. Blood, 2015, 126, 5009-5009.	1.4	0
48	MP09-15â€ƒ68GA-PSMA-11 PET/CT IN RECURRENT PROSTATE CANCER: EFFICACY IN DIFFERENT CLINICAL STAGES OF PSA FAILURE. Journal of Urology, 2019, 201, .	0.4	0